Affiliation: National Institutes of Health
- National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communitiesWorta McCaskill-Stevens
Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA
Clin Trials 10:280-91. 2013....
- Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical AssociationW McCaskill-Stevens
Division of Cancer Prevention, National Cancer Institute National Institutes of Health, Rockville, MD 20852, USA
J Clin Oncol 17:1029-39. 1999..The Eastern Cooperative Oncology Group (ECOG) conducted a study to identify barriers and solutions to African American accrual onto clinical trials...
- Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifenWorta McCaskill-Stevens
CORE Investigators National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, EPN 2014, Bethesda, MD 20892, USA
J Natl Cancer Inst 96:1762-9. 2004..Information about breast cancer treatment and prevention in African American women is scant, and recommendations for therapy from clinical trials for breast cancer are based primarily on data obtained from white women...
- Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experienceWorta McCaskill-Stevens
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 23:5247-54. 2005..This article examines temporal trends in MBCCOP accruals to cancer prevention and control (CP/C) and cancer treatment trials and the racial distribution of study participants, along with the major factors affecting minority enrollment...
- Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or olderAndrew N Freedman
Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, Bethesda, MD 20892, USA
J Clin Oncol 29:2327-33. 2011..There is a need to summarize the risks and benefits of these agents...
- Projecting individualized absolute invasive breast cancer risk in African American womenMitchell H Gail
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Plaza South Rm 8032, Bethesda, MD 20892 7244, USA
J Natl Cancer Inst 99:1782-92. 2007..We developed a model for projecting absolute risk of invasive breast cancer in African American women and compared its projections with those from the Breast Cancer Risk Assessment Tool...
- Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemopreventionAndrew N Freedman
Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7344, USA
J Natl Cancer Inst 95:526-32. 2003..67% or higher for breast cancer chemoprevention. However, tamoxifen use has been associated with adverse outcomes, and not all eligible women have a positive benefit/risk ratio...
- Prevention and early detection clinical trials: opportunities for primary care providers and their patientsLeslie G Ford
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
CA Cancer J Clin 53:82-101. 2003....
- Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology ProgramLori M Minasian
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
Cancer 116:4440-9. 2010..By describing its keys to success, this article provides practical guidance to cancer-focused, provider-based research networks as well as those in other disciplines...
- Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597Daniel D Karp
Daniel D Karp, The University of Texas MD Anderson Cancer Center, Houston David H Johnson, University of Texas Southwestern, Dallas, TX Sandra J Lee, Dana Farber Cancer Institute, Boston, MA Steven M Keller, Montefiore Medical Center, Bronx, NY Gail Shaw Wright, Florida Cancer Specialists, New Port Richey, FL Seena Aisner, University of Medicine and Dentistry of New Jersey New Jersey Medical School Cancer Institute of New Jersey, Newark, NJ Steven Alan Belinsky, Lovelace Respiratory Research Institute, Albuquerque, NM Gary Goodman, Swedish Medical Center Cancer Institute Gary Goodman, Fred Hutchinson Cancer Research Center, Seattle, WA Gerald Clamon, University of Iowa, Iowa City, IA Randolph Marks, Mayo Clinic, Rochester, MN Worta McCaskill Stevens, National Cancer Institute, Rockville, MD Scott M Lippman, University of California San Diego Cancer Center, San Diego, CA John Ruckdeschel, Intermountain Healthcare, Salt Lake City, UT Fadlo R Khuri, Emory University, Atlanta, GA Michael R Johnston
J Clin Oncol 31:4179-87. 2013..We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation...
- Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trialsDavid R Buchanan
Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
Cancer 110:1621-8. 2007..Finally, there is a growing appreciation that trials must be powered to test for effects on secondary endpoints...
- Barriers to racial/ethnic minority application and competition for NIH research fundingVickie L Shavers
National Cancer Institute, Division of Cancer Control and Population Sciences, Applied Research Program HSEB, 6130 Executive Blvd EPN 4005 MSC 7344, Bethesda, MD 20892 7344, USA
J Natl Med Assoc 97:1063-77. 2005....
- Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialVictor G Vogel
Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
JAMA 295:2727-41. 2006..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis...
- Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedingsMark Messina
Department of Nutrition, School of Public Health, Loma Linda University, Loma Linda, CA, USA
J Natl Cancer Inst 98:1275-84. 2006..This paper summarizes the workshop findings and recommendations. The primary research recommendation is that the impact of isoflavones on breast tissue needs to be evaluated at the cellular level in women at high risk for breast cancer...